News
NHS England also publishes a figure for the median wait, in weeks, for cases where someone has not started to receive treatment yet. Because it’s the median, this number shows what you would see if ...
Many patients can expect a long wait for access to Eli Lilly's obesity shot Mounjaro, even though it has been recommended for routine NHS use by NICE.
Outlook Therapeutics' Lytenava is the first ophthalmic formulation of bevacizumab to be cleared for use by NICE for use in the NHS for wet AMD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results